A practical reference on purity certificate: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-04 and is reviewed periodically as new material appears.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
A ketogenic amino acid is an amino acid that can be degraded directly into acetyl-CoA, which is the precursor of ketone bodies and myelin, particularly during early childhood, when the developing brain requires high rates of myelin synthesis. This is in contrast to the glucogenic amino acids, which are converted into glucose. Ketogenic amino acids are unable to be converted to glucose as both carbon atoms in the ketone body are ultimately degraded to carbon dioxide in the citric acid cycle. In humans, two amino acids – leucine and lysine – are exclusively ketogenic. Five more are amphibolic (both ketogenic and glucogenic): phenylalanine, isoleucine, threonine, tryptophan and tyrosine. The remaining thirteen are exclusively glucogenic.
1985–1987 – 1.3 L (1,296 cc) E3, 2 barrel, 8-valve, 74 PS (54 kW; 73 hp) Gross / 10.5 kg⋅m (103 N⋅m; 76 lb⋅ft) 1987–1989 – 1.3 L (1,323 cc) B3, 2 barrel, 8-valve, 67 PS (49 kW; 66 hp) Net / 10.4 kg⋅m (102 N⋅m; 75 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5, 2 barrel carburettor, 8-valve, 85 PS (63 kW; 84 hp) Gross / 12.3 kg⋅m (121 N⋅m; 89 lb⋅ft) Gross – Net rating 70 PS (51 kW; 69 hp) / 11.2 kg⋅m (110 N⋅m; 81 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5, EGi, 8-valve, 95 PS (70 kW; 94 hp) Gross/12.6 kg⋅m (124 N⋅m; 91 lb⋅ft) Gross – Net rating 76 PS (56 kW; 75 hp) / 11.6 kg⋅m (114 N⋅m; 84 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5T, turbo EGi, 8-valve, 115 PS (85 kW; 113 hp) Gross / 16.5 kg⋅m (162 N⋅m; 119 lb⋅ft) 1987–1989 – 1.5 L (1,498 cc) B5, 2 barrel, 12-valve, 76 PS (56 kW; 75 hp) Net / 11.4 kg⋅m (112 N⋅m; 82 lb⋅ft) 1987–1989 – 1.6 L (1,597 cc) B6, EGi, 8-valve, 85 PS (63 kW; 84 hp) Net / 12.5 kg⋅m (123 N⋅m; 90 lb⋅ft) 1986–1989 – 1.6 L (1,597 cc) B6D, EGi, 16-valve, 110 PS (81 kW; 108 hp) Net / 13.5 kg⋅m (132 N⋅m; 98 lb⋅ft) 1985–1989 – 1.6 L (1,597 cc) B6T, turbo EGi, 16-valve, 140 PS (103 kW; 138 hp) Net / 19.0 kg⋅m (186 N⋅m; 137 lb⋅ft) 1985–1989 – 1.7 L (1,720 cc) PN, diesel, 8-valve, 59 PS (43 kW; 58 hp) Gross / 10.8 kg⋅m (106 N⋅m; 78 lb⋅ft) Gross – Net rating 55 PS (40 kW; 54 hp) / 10.2 kg⋅m (100 N⋅m; 74 lb⋅ft), 1987–1989; Net rating: 58 PS (43 kW; 57 hp) / 10.7 kg⋅m (105 N⋅m; 77 lb⋅ft)
== External links == "Relaxin Family Peptide Receptors: RXFP2". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-09. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Its quadrupole moment causes line broadening. Used in metabolic and biochemical studies of chemical equilibria. 19F, spin-1/2, relatively commonly measured. Sensitive, yields sharp signals, has a wide chemical shift range. 31P, spin-1/2, 100% of natural phosphorus. Medium sensitivity, wide chemical shift range, yields sharp lines. Spectra tend to have a moderate level of noise. Used in biochemical studies and in coordination chemistry with phosphorus-containing ligands. 35Cl and 37Cl, spin-3/2, broad signal. 35Cl is significantly more sensitive, preferred over 37Cl despite its slightly broader signal. Organic chlorides yield very broad signals. Its use is limited to inorganic and ionic chlorides and very small organic molecules. 43Ca, spin-7/2, relatively small quadrupole moment, moderately sensitive, very low natural abundance. Used in biochemistry to study calcium binding to DNA, proteins, etc. 195Pt, used in studies of catalysts and complexes. Other nuclei (usually used in the studies of their complexes and chemical bonding, or to detect presence of the element):
Sources: en.wikipedia.org
A series of steps catalyzed in part by the recombinase then leads to joining of the two helices by at least one Holliday junction, in which a segment of a single strand in each helix is annealed to the complementary strand in the other helix. The Holliday junction is a tetrahedral junction structure that can be moved along the pair of chromosomes, swapping one strand for another. The recombination reaction is then halted by cleavage of the junction and re-ligation of the released DNA. Only strands of like polarity exchange DNA during recombination. There are two types of cleavage: east-west cleavage and north–south cleavage. The north–south cleavage nicks both strands of DNA, while the east–west cleavage has one strand of DNA intact. The formation of a Holliday junction during recombination makes it possible for genetic diversity, genes to exchange on chromosomes, and expression of wild-type viral genomes.
=== Environmental === Environmental biotechnology includes various disciplines that play an essential role in reducing environmental waste and providing environmentally safe processes, such as biofiltration and biodegradation. The environment can be affected by biotechnologies, both positively and adversely. Vallero and others have argued that the difference between beneficial biotechnology (e.g., bioremediation is to clean up an oil spill or hazard chemical leak) versus the adverse effects stemming from biotechnological enterprises (e.g., flow of genetic material from transgenic organisms into wild strains) can be seen as applications and implications, respectively. Cleaning up environmental wastes is an example of an application of environmental biotechnology; whereas loss of biodiversity or loss of containment of a harmful microbe are examples of environmental implications of biotechnology. Many cities have installed CityTrees, which use biotechnology to filter pollutants from urban atmospheres.
Amyr Klink (born 25 September 1955) is a Brazilian explorer, sailor and writer. One of his projects, "Antarctica 360", was circumnavigating the Antarctic continent on his own, in 88 days between 1998 and 1999.
Sources: en.wikipedia.org
Glycerin may generate acrolein when heated at hotter temperatures. Some e-cigarette products had acrolein identified in the e-cigarette vapor, at greatly lower amounts than in cigarette smoke. Several e-cigarette companies have replaced glycerin and propylene glycol with ethylene glycol. In 2014, most e-cigarettes companies began to use water and glycerin as replacement for propylene glycol. In 2015, manufacturers attempted to reduce the formation of formaldehyde and metal substances of the e-cigarette vapor by producing an e-liquid in which propylene glycol is replaced by glycerin. Acetol, beta-nicotyrine, butanal, crotonaldehyde, glyceraldehyde, glycidol, glyoxal, dihydroxyacetone, dioxolanes, lactic acid, methylglyoxal, myosmine, oxalic acid, propanal, pyruvic acid, and vinyl alcohol isomers have been found in the e-cigarette vapor. Hydroxymethylfurfural and furfural have been found in the e-cigarette vapors. The amounts of furans in the e-cigarette vapors were highly associated with power of the e-cigarette and amount of sweetener. The amount of carbonyls vary greatly among different companies and within various samples of the same e-cigarettes. Oxidants and reactive oxygen species (OX/ROS) have been found in the e-cigarette vapor. OX/ROS could react with other chemicals in the e-cigarette vapor because they are highly reactive, causing alterations its chemical composition. E-cigarette vapor have been found to contain OX/ROS at about 100 times less than with cigarette smoke.
ectopic Occurring or developing in an abnormal place or position or in an unusual form or manner; displaced, malpositioned, or produced in an unnatural context. For example, ectopic expression refers to the expression of a particular gene product in a cell or tissue where it is not normally expressed. Contrast entopic.
== Biochemical function == β-Alanine residues are rare. It is a component of the peptides carnosine and anserine and also of pantothenic acid (vitamin B5), which itself is a component of coenzyme A. β-alanine is metabolized into acetic acid.
Stereoselective activation: Stereoselective activation of (R)-profen by the formation of the thioester, in the presence of CoA, ATP and Mg+2. (S)-profen does not form the thioester. Epimerization (Racemization): The enzyme epimerase 2-arylpropionic-CoA changes the (R)-thioester to the (S)-thioester. This process is called "racemization" or "epimerization." Hydrolysis: With the help of hydrolase/thioesterase, thioesters are broken down into their (R)- and (S)-forms Because the acyl-CoA thioester (profenyl-CoA) changes the structure of triglycerides and phospholipids, metabolic chiral inversion may cause toxic effects.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.